Elsevier

JACC: Heart Failure

Volume 8, Issue 5, May 2020, Pages 369-371
JACC: Heart Failure

Special Focus Issue: Biomarkers
Editorial Comment
Should Enrichment With Natriuretic Peptide Levels Be Mandatory in Global Clinical Trials?

https://doi.org/10.1016/j.jchf.2020.01.007Get rights and content
Under an Elsevier user license
open archive

Key Words

cardiac biomarkers
clinical trials
heart failure with reduced ejection fraction

Cited by (0)

Dr. Voor is a consultant for and has received support from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, MyoKardia, Novartis, NovoNordisk, and Roche Diagnostics.

The author attests they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Heart Failure author instructions page.

Editorials published in JACC: Heart Failure reflect the views of the authors and do not necessarily represent the views of JACC: Heart Failure or the American College of Cardiology.